LIVIVO - Search results -

Search results

Result 1 - 10 of total 773

Search options

Article: Pour une co-construction de l’offre de soins.

Verheye, Jean-Charles / Poirel, Carole

2017 Volume 62, Issue 812, Page(s) 16–19

Abstract: The deployment of quality approaches in hospitals and the evolution of the place of users in the health care system is resulting in patients becoming more involved in the quality of care. Taking into consideration the contribution of collaborative ... ...

Title translation	For a co-construction of the health care provision.
Abstract	The deployment of quality approaches in hospitals and the evolution of the place of users in the health care system is resulting in patients becoming more involved in the quality of care. Taking into consideration the contribution of collaborative practices is necessary in order to enable patients and caregivers to work together effectively, and to improve the quality of care. Finally, the recognition of patients' expertise and the implementation of adapted methods allow different points of view to come together and decisions to be made jointly.
MeSH term(s)	Communication ; Cooperative Behavior ; Decision Making ; Democracy ; Health Personnel/organization & administration ; Humans ; Patient Care Team/organization & administration ; Patient Care Team/standards ; Patient Participation ; Professional-Patient Relations ; Quality of Health Care/organization & administration ; Quality of Health Care/standards
Language	French
Publishing date	2017-01
Publishing country	France
Document type	Journal Article
ZDB-ID	604655-1
ISSN	0038-0814
ISSN	0038-0814
DOI	10.1016/j.soin.2016.12.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2545: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comment on: Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers.

Nordmann, Patrice / Poirel, Laurent

The Journal of antimicrobial chemotherapy

2022 Volume 77, Issue 4, Page(s) 1209

MeSH term(s)	Anti-Bacterial Agents/therapeutic use ; Bacterial Proteins ; Carbapenems/pharmacology ; Microbial Sensitivity Tests ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; Bacterial Proteins ; Carbapenems ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2022-01-13
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkab480
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of

Le Terrier, Christophe / Nordmann, Patrice / Buchs, Chloé / Poirel, Laurent

Antimicrobial agents and chemotherapy

2024 Volume 68, Issue 4, Page(s) e0154823

Abstract: The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified ... ...

Abstract	The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in
MeSH term(s)	Aztreonam/pharmacology ; Meropenem/pharmacology ; Cefiderocol ; Cefepime/pharmacology ; Penicillin-Binding Proteins ; Escherichia coli ; beta-Lactamases/metabolism ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Azabicyclo Compounds/chemistry ; Drug Combinations ; Imipenem/pharmacology ; Imipenem/chemistry ; Microbial Sensitivity Tests ; Borinic Acids ; Boronic Acids ; Carboxylic Acids ; Ceftazidime
Chemical Substances	relebactam (Y1MYA2UHFL) ; avibactam, ceftazidime drug combination ; avibactam (7352665165) ; Aztreonam (G2B4VE5GH8) ; Meropenem (FV9J3JU8B1) ; Cefiderocol (SZ34OMG6E8) ; Cefepime (807PW4VQE3) ; Penicillin-Binding Proteins ; vaborbactam (1C75676F8V) ; taniborbactam (8IGQ156Z07) ; beta-Lactamases (EC 3.5.2.6) ; Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; Imipenem (71OTZ9ZE0A) ; Borinic Acids ; Boronic Acids ; Carboxylic Acids ; Ceftazidime (9M416Z9QNR)
Language	English
Publishing date	2024-02-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	217602-6
ISSN	1098-6596 ; 0066-4804
ISSN (online)	1098-6596
ISSN	0066-4804
DOI	10.1128/aac.01548-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 809: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023.

Findlay, Jacqueline / Raro, Otavio Hallal Ferreira / Poirel, Laurent / Nordmann, Patrice

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2024 Volume 43, Issue 3, Page(s) 551–557

Abstract: Objectives: The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates ... ...

Abstract	Objectives: The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) reference laboratory over a 12-month period from July 2022 to July 2023. Methods: Thirty-nine non-duplicate MBL-PA Isolates were submitted to NARA over the study period from across Switzerland. Susceptibility was determined by broth microdilution according to EUCAST methodology. Whole-genome sequencing was performed on 34 isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. MBL genes, bla Results: The most prevalent MBL types identified in this study were VIM (21/39; 53.8%) followed by NDM (11/39; 28.2%), IMP (6/39; 15.4%), and a single isolate produced both VIM and NDM enzymes. WGS identified 13 different STs types among the 39 isolates. They all exhibited resistance to cephalosporins, carbapenems, and the beta-lactam-beta-lactamase inhibitor combinations, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, and 8 isolates were cefiderocol (FDC) resistant. Recombinant P. aeruginosa strains producing bla Conclusions: This study showed that the MBL-PA in Switzerland could be attributed to the wide dissemination of high-risk clones that accounted for most isolates in this study. Although FDC resistance was only found in 8 isolates, MBL carriage was shown to be a major contributor to this phenotype.
MeSH term(s)	Humans ; Pseudomonas aeruginosa ; Switzerland/epidemiology ; beta-Lactamases/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Carbapenems/pharmacology ; Microbial Sensitivity Tests ; Pseudomonas Infections/microbiology
Chemical Substances	beta-Lactamases (EC 3.5.2.6) ; Anti-Bacterial Agents ; Carbapenems
Language	English
Publishing date	2024-01-18
Publishing country	Germany
Document type	Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-024-04752-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates.

Findlay, Jacqueline / Poirel, Laurent / Nordmann, Patrice

Journal of global antimicrobial resistance

2023 Volume 32, Page(s) 66–71

Abstract: Objectives: A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC)- ... ...

Abstract	Objectives: A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales. The purpose of this study was to select for MEM-VAB resistance using a collection of eight KPC-producing K. pneumoniae clinical isolates, including three that produce KPC variants conferring ceftazidime-avibactam (CAZ-AVI) resistance, and subsequently decipher the corresponding resistance mechanisms. Methods: Mutants were selected in a stepwise process on agar plates containing different MEM-VAB concentrations. Susceptibility testing was performed by broth microdilution, and complementation assays were performed with wildtype ompK36. Whole genome sequencing was performed on mutants, and KPC copy number was assessed by quantitative polymerase chain reaction . Results: Mutants were obtained from 6/8 tested isolates and reduced susceptibility to all tested β-lactams, and BLBIs, including CAZ-AVI, imipenem-relebactam, and aztreonam-AVI, were observed. No mutations were identified in the bla Conclusions: In contrast to what is observed with KPC-producing mutants exhibiting resistance to CAZ-AVI, mainly corresponding to mutated KPC enzymes, here the MEM-VAB-resistant mutants showed permeability defects combined with increased KPC production, resulting from genomic rearrangement.
MeSH term(s)	Humans ; Meropenem/pharmacology ; Klebsiella pneumoniae/genetics ; Klebsiella Infections
Chemical Substances	Meropenem (FV9J3JU8B1) ; carbapenemase (EC 3.5.2.6) ; vaborbactam (1C75676F8V)
Language	English
Publishing date	2023-01-14
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2710046-7
ISSN	2213-7173 ; 2213-7173
ISSN (online)	2213-7173
ISSN	2213-7173
DOI	10.1016/j.jgar.2022.12.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.

Nordmann, Patrice / Bouvier, Maxime / Poirel, Laurent

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2023 Volume 42, Issue 9, Page(s) 1145–1152

Abstract: Carbapenemase-producing in Enterobacterales (CPE) represent a critical health concern worldwide, including in Switzerland, leading to very limited therapeutic options. Therefore, our aim was to evaluate the susceptibility to the novel ß-lactam/ß- ... ...

Abstract	Carbapenemase-producing in Enterobacterales (CPE) represent a critical health concern worldwide, including in Switzerland, leading to very limited therapeutic options. Therefore, our aim was to evaluate the susceptibility to the novel ß-lactam/ß-lactamase inhibitor combinations ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam of CPE isolates recovered in Switzerland from 2018 to 2020. A total of 150 clinical CPE were studied including mainly Klebsiella pneumoniae (n = 61, 40.3%) and Escherichia coli (n = 53, 35.3%). The distribution of carbapenemases was as follows: KPC-like (32%), OXA-48-like (32%), NDM-like (24%), combinations of carbapenemases (10%), VIM-1 producers (n = 2), and a single IMI-1 producer. Overall, 77% of the strains were susceptible to meropenem-vaborbactam, 63% was susceptible to ceftazidime-avibactam, and 62% susceptible to imipenem-relebactam. Those data may contribute to optimize the choice of first line therapy for treating infections due to CPE.
MeSH term(s)	Humans ; Meropenem/pharmacology ; Switzerland ; Anti-Bacterial Agents/pharmacology ; Ceftazidime/pharmacology ; beta-Lactamases ; Bacterial Proteins/genetics ; Drug Combinations ; Imipenem/pharmacology ; Microbial Sensitivity Tests ; Klebsiella pneumoniae
Chemical Substances	avibactam, ceftazidime drug combination ; relebactam (Y1MYA2UHFL) ; Meropenem (FV9J3JU8B1) ; carbapenemase (EC 3.5.2.6) ; vaborbactam (1C75676F8V) ; Anti-Bacterial Agents ; Ceftazidime (9M416Z9QNR) ; beta-Lactamases (EC 3.5.2.6) ; Bacterial Proteins ; Drug Combinations ; Imipenem (71OTZ9ZE0A)
Language	English
Publishing date	2023-08-11
Publishing country	Germany
Document type	Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-023-04647-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Effect of Zinc Oxide and Copper Sulfate on Antibiotic Resistance Plasmid Transfer in

Raro, Otávio Hallal Ferreira / Poirel, Laurent / Nordmann, Patrice

Microorganisms

2023 Volume 11, Issue 12

Abstract: Heavy metals such as zinc (Zn) and copper (Cu) may be associated with antibiotic resistance dissemination. Our aim was to investigate whether sub-lethal dosage of Zn and Cu may enhance plasmid transfer and subsequently resistance genes dissemination. ... ...

Abstract	Heavy metals such as zinc (Zn) and copper (Cu) may be associated with antibiotic resistance dissemination. Our aim was to investigate whether sub-lethal dosage of Zn and Cu may enhance plasmid transfer and subsequently resistance genes dissemination. Plasmid conjugation frequencies (PCF) were performed with
Language	English
Publishing date	2023-11-29
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720891-6
ISSN	2076-2607
ISSN	2076-2607
DOI	10.3390/microorganisms11122880
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rapid detection of temocillin resistance in Enterobacterales.

Findlay, Jacqueline / Poirel, Laurent / Nordmann, Patrice

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 11, Page(s) 2770–2771

MeSH term(s)	Penicillins ; Anti-Bacterial Agents/pharmacology ; Gammaproteobacteria ; Microbial Sensitivity Tests
Chemical Substances	temocillin (03QB156W6I) ; Penicillins ; Anti-Bacterial Agents
Language	English
Publishing date	2023-08-08
Publishing country	England
Document type	Research Support, Non-U.S. Gov't ; Letter
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad243
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.

Le Terrier, Christophe / Nordmann, Patrice / Sadek, Mustafa / Poirel, Laurent

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 5, Page(s) 1191–1194

Abstract: ... with MIC50 and MIC90 being at 16 mg/L and 64 mg/L, respectively. Conversely, all strains were susceptible ... to cefepime/zidebactam, with both MIC50 and MIC90 at 0.25 mg/L. Notably, all strains showed low MICs ... for zidebactam alone, with MIC50 and MIC90 at 0.5 mg/L and 1 mg/L.: Conclusions: Our data highlighted ...

Abstract	Background: Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales. However, PBP3-modified and NDM-producing Escherichia coli strains that co-produce CMY-42 have been shown to be resistant to this drug combination. The aim of our study was to assess the in vitro activity of cefepime/taniborbactam and cefepime/zidebactam against such aztreonam/avibactam-resistant E. coli strains. Methods: MIC values of aztreonam, aztreonam/avibactam, cefepime, cefepime/taniborbactam, cefepime/zidebactam and zidebactam alone were determined for 28 clinical aztreonam/avibactam-resistant E. coli isolates. Those isolates produced either NDM-5 (n = 24), NDM-4 (n = 2) or NDM-1 (n = 2), and they all co-produced CMY-42 (n = 28). They all harboured a four amino acid insertion in PBP-3 (Tyr-Arg-Ile-Asn or Tyr-Arg-Ile-Lys). Results: All strains were resistant to aztreonam/avibactam and cefepime, as expected. The resistance rate to cefepime/taniborbactam was 100%, with MIC50 and MIC90 being at 16 mg/L and 64 mg/L, respectively. Conversely, all strains were susceptible to cefepime/zidebactam, with both MIC50 and MIC90 at 0.25 mg/L. Notably, all strains showed low MICs for zidebactam alone, with MIC50 and MIC90 at 0.5 mg/L and 1 mg/L. Conclusions: Our data highlighted the excellent in vitro performance of the newly developed β-lactam/β-lactamase inhibitor combination cefepime/zidebactam against aztreonam/avibactam-resistant E. coli strains, suggesting that this combination could be considered as an efficient therapeutic option in this context. Our study also highlights the cross-resistance between acquired resistance to aztreonam/avibactam and the cefepime/taniborbactam combination.
MeSH term(s)	Aztreonam/pharmacology ; Cefepime/pharmacology ; Escherichia coli ; Anti-Bacterial Agents/pharmacology ; beta-Lactamases/metabolism ; Cephalosporins/pharmacology ; Azabicyclo Compounds/pharmacology ; beta-Lactamase Inhibitors/pharmacology ; Microbial Sensitivity Tests
Chemical Substances	Aztreonam (G2B4VE5GH8) ; Cefepime (807PW4VQE3) ; zidebactam ; Anti-Bacterial Agents ; avibactam (7352665165) ; taniborbactam (8IGQ156Z07) ; beta-Lactamases (EC 3.5.2.6) ; Cephalosporins ; Azabicyclo Compounds ; beta-Lactamase Inhibitors
Language	English
Publishing date	2023-03-24
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad061
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

Le Terrier, Christophe / Freire, Samanta / Nordmann, Patrice / Poirel, Laurent

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2023 Volume 43, Issue 2, Page(s) 339–354

Abstract: ... showing MIC values of cefiderocol being ≥1 mg/L. If unavailable, the respective β-lactam breakpoints ...

Abstract	Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem-nacubactam, and sulbactam-durlobactam against clinical isolates showing reduced susceptibility or resistance to cefiderocol in Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. Methods: MIC values of aztreonam, aztreonam-avibactam, cefepime, cefepime-taniborbactam, cefepime-zidebactam, imipenem, imipenem-relebactam, meropenem, meropenem-vaborbactam, meropenem-nacubactam, sulbactam-durlobactam, and cefiderocol combined with a BLI were determined for 67, 9, and 11 clinical Enterobacterales, P. aeruginosa or A. baumannii isolates, respectively, showing MIC values of cefiderocol being ≥1 mg/L. If unavailable, the respective β-lactam breakpoints according to EUCAST were used for BL/BLI combinations. Results: For Enterobacterales, the susceptibility rates for aztreonam, cefepime, imipenem, and meropenem were 7.5%, 0%, 10.4%, and 10.4%, respectively, while they were much higher for cefepime-zidebactam (91%), cefiderocol-zidebactam (91%), meropenem-nacubactam (71.6%), cefiderocol-nacubactam (74.6%), and cefiderocol-taniborbactam (76.1%), as expected. For P. aeruginosa isolates, the higher susceptibility rates were observed for imipenem-relebactam, cefiderocol-zidebactam, and meropenem-vaborbactam (56% for all combinations). For A. baumannii isolates, lower susceptibility rates were observed with commercially or under development BL/BLI combos; however, a high susceptibility rate (70%) was found for sulbactam-durlobactam and when cefiderocol was associated to some BLIs. Conclusions: Zidebactam- and nacubactam-containing combinations showed a significant in vitro activity against multidrug-resistant Enterobacterales clinical isolates with reduced susceptibility to cefiderocol. On the other hand, imipenem-relebactam and meropenem-vaborbactam showed the highest susceptibility rates against P. aeruginosa isolates. Finally, sulbactam-durlobactam and cefiderocol combined with a BLI were the only effective options against A. baumannii tested isolates.
MeSH term(s)	Humans ; Cefiderocol ; Meropenem/pharmacology ; Cefepime ; Aztreonam/pharmacology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Cephalosporins/pharmacology ; Imipenem/pharmacology ; beta-Lactamase Inhibitors/pharmacology ; Microbial Sensitivity Tests ; beta-Lactamases ; Carboxylic Acids ; Piperidines ; Lactams ; Boronic Acids ; Cyclooctanes ; Azabicyclo Compounds ; Borinic Acids
Chemical Substances	relebactam (Y1MYA2UHFL) ; zidebactam ; nacubactam (832O37V7MZ) ; Cefiderocol (SZ34OMG6E8) ; Meropenem (FV9J3JU8B1) ; avibactam (7352665165) ; vaborbactam (1C75676F8V) ; taniborbactam (8IGQ156Z07) ; Cefepime (807PW4VQE3) ; Aztreonam (G2B4VE5GH8) ; Anti-Bacterial Agents ; Cephalosporins ; Imipenem (71OTZ9ZE0A) ; beta-Lactamase Inhibitors ; beta-Lactamases (EC 3.5.2.6) ; Carboxylic Acids ; Piperidines ; Lactams ; Boronic Acids ; Cyclooctanes ; Azabicyclo Compounds ; Borinic Acids
Language	English
Publishing date	2023-12-14
Publishing country	Germany
Document type	Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-023-04732-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito